Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

19 trials with published results (8%)

Research Maturity

148 completed trials (59% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

6.0%

15 terminated out of 252 trials

Success Rate

90.8%

+4.3% vs benchmark

Late-Stage Pipeline

3%

8 trials in Phase 3/4

Results Transparency

13%

19 of 148 completed with results

Key Signals

19 with results91% success15 terminated

Data Visualizations

Phase Distribution

159Total
Not Applicable (83)
Early P 1 (5)
P 1 (27)
P 2 (36)
P 3 (1)
P 4 (7)

Trial Status

Completed148
Recruiting34
Unknown30
Terminated15
Enrolling By Invitation6
Active Not Recruiting6

Trial Success Rate

90.8%

Benchmark: 86.5%

Based on 148 completed trials

Clinical Trials (252)

Showing 20 of 20 trials
NCT06657001Enrolling By Invitation

Enabling Microbiomics- Driven Personalized Nutrition

NCT06310291Early Phase 1RecruitingPrimary

VTP-1000 in Adults With Celiac Disease

NCT06059716Not ApplicableRecruitingPrimary

Gluten Technology and Education for Celiac Health

NCT05094232CompletedPrimary

Coeliac Disease in Spain: Determination of Disease Prevalence and Risk Factors

NCT07239336Phase 2RecruitingPrimary

Study of DONQ52 in Active Celiac Disease

NCT07585669Not ApplicableRecruitingPrimary

Effects of Omega-3 Fatty Acids on Inflammation and Gut Microbiota in Celiac Disease

NCT07584473Not ApplicableRecruiting

NCWS or IBS/FD in Relatives of CD Patients

NCT05680012Not ApplicableRecruitingPrimary

Tissue Destruction and Healing in Celiac Disease

NCT06178107Not ApplicableCompletedPrimary

Efficacy of Cholesterol-lowering L. Plantarum on Cardiometabolic Health Biomarkers in Coeliac Disease Patients

NCT03351972Phase 4Completed

Differences in Preparation for Small Bowel Capsule Endoscopy

NCT07556328RecruitingPrimary

Histomolecular Profiling in Small-Bowel Diseases

NCT07362654Not ApplicableRecruitingPrimary

Single-cell Immune Response to Controlled Gluten Ingestion in Pediatric Celiac Disease

NCT06151782Not ApplicableCompletedPrimary

Immunosafe-CeD: Are Partially Hydrolysed Gluten Harmful to Celiac Disease Patients?

NCT07069127Not ApplicableRecruitingPrimary

Hydroxyapatite-Based Home Treatment for Dentin Sensitivity in Celiac Patients

NCT07377565Phase 1RecruitingPrimary

A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

NCT07063823Phase 1CompletedPrimary

A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

NCT06908057Active Not Recruiting

Accessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D)

NCT07039773Not ApplicableRecruitingPrimary

Gluten Challenge in Celiac Disease - Which Formulation of Gluten Gives the Best Response?

NCT05636293Phase 2CompletedPrimary

Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

NCT02061306RecruitingPrimary

Celiac Disease Genomic Environmental Microbiome and Metabolomic Study

Scroll to load more

Research Network

Activity Timeline